Protagonist Therapeutics, Inc — Director's Dealing 2021

Aug 19, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Protagonist Therapeutics, Inc (PTGX)
CIK: 0001377121
Period of Report: 2021-08-17

Reporting Person: Liu David Y (Chief Scientific Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-08-17	Common Stock	M	10000	$0.87	Acquired	73033	Direct
2021-08-17	Common Stock	S	14779	$47.56	Disposed	58254	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-08-17	Stock Option (right to buy)	$0.87	M	10000	Disposed	2023-09-26	Common Stock (10000)	Direct

Footnotes

F1: Includes an aggregate of 606 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on March 9, 2021.

F2: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 7, 2021.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.10 to $48.34. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F4: The stock option is vested in full.